Literature DB >> 24352465

Pathogenic mutations within the hydrophobic domain of the prion protein lead to the formation of protease-sensitive prion species with increased lethality.

Bradley M Coleman1, Christopher F Harrison, Belinda Guo, Colin L Masters, Kevin J Barnham, Victoria A Lawson, Andrew F Hill.   

Abstract

UNLABELLED: Prion diseases are a group of fatal and incurable neurodegenerative diseases affecting both humans and animals. The principal mechanism of these diseases involves the misfolding the host-encoded cellular prion protein, PrP(C), into the disease-associated isoform, PrP(Sc). Familial forms of human prion disease include those associated with the mutations G114V and A117V, which lie in the hydrophobic domain of PrP. Here we have studied the murine homologues (G113V and A116V) of these mutations using cell-based and animal models of prion infection. Under normal circumstances, the mutant forms of PrP(C) share similar processing, cellular localization, and physicochemical properties with wild-type mouse PrP (MoPrP). However, upon exposure of susceptible cell lines expressing these mutants to infectious prions, very low levels of protease-resistant aggregated PrP(Sc) are formed. Subsequent mouse bioassay revealed high levels of infectivity present in these cells. Thus, these mutations appear to limit the formation of aggregated PrP(Sc), giving rise to the accumulation of a relatively soluble, protease sensitive, prion species that is highly neurotoxic. Given that these mutations lie next to the glycine-rich region of PrP that can abrogate prion infection, these findings provide further support for small, protease-sensitive prion species having a significant role in the progression of prion disease and that the hydrophobic domain is an important determinant of PrP conversion. IMPORTANCE: Prion diseases are transmissible neurodegenerative diseases associated with an infectious agent called a prion. Prions are comprised of an abnormally folded form of the prion protein (PrP) that is normally resistant to enzymes called proteases. In humans, prion disease can occur in individuals who inherited mutations in the prion protein gene. Here we have studied the effects of two of these mutations and show that they influence the properties of the prions that can be formed. We show that the mutants make highly infectious prions that are more sensitive to protease treatment. This study highlights a certain region of the prion protein as being involved in this effect and demonstrates that prions are not always resistant to protease treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24352465      PMCID: PMC3958101          DOI: 10.1128/JVI.02720-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  88 in total

1.  Creutzfeldt-Jakob disease with PRNP G114V mutation in a Chinese family.

Authors:  Z Liu; L Jia; Y Piao; D Lu; F Wang; H Lv; Y Lu; J Jia
Journal:  Acta Neurol Scand       Date:  2009-12-17       Impact factor: 3.209

2.  Characterization of detergent-insoluble complexes containing the cellular prion protein and its scrapie isoform.

Authors:  N Naslavsky; R Stein; A Yanai; G Friedlander; A Taraboulos
Journal:  J Biol Chem       Date:  1997-03-07       Impact factor: 5.157

3.  Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes).

Authors:  R M Johnstone; M Adam; J R Hammond; L Orr; C Turbide
Journal:  J Biol Chem       Date:  1987-07-05       Impact factor: 5.157

4.  Extended period of asymptomatic prion disease after low dose inoculation: assessment of detection methods and implications for infection control.

Authors:  Steven J Collins; Victoria Lewis; Marcus W Brazier; Andrew F Hill; Victoria A Lawson; Genevieve M Klug; Colin L Masters
Journal:  Neurobiol Dis       Date:  2005-11       Impact factor: 5.996

5.  A novel mutation (G114V) in the prion protein gene in a family with inherited prion disease.

Authors:  M-M Rodriguez; K Peoc'h; S Haïk; C Bouchet; L Vernengo; G Mañana; R Salamano; L Carrasco; M Lenne; P Beaudry; J-M Launay; J-L Laplanche
Journal:  Neurology       Date:  2005-04-26       Impact factor: 9.910

6.  Altered toxicity of the prion protein peptide PrP106-126 carrying the Ala(117)-->Val mutation.

Authors:  D R Brown
Journal:  Biochem J       Date:  2000-03-15       Impact factor: 3.857

Review 7.  Prion diseases of humans and animals: their causes and molecular basis.

Authors:  J Collinge
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

Review 8.  A beta oligomers - a decade of discovery.

Authors:  Dominic M Walsh; Dennis J Selkoe
Journal:  J Neurochem       Date:  2007-02-05       Impact factor: 5.372

9.  A novel protective prion protein variant that colocalizes with kuru exposure.

Authors:  Simon Mead; Jerome Whitfield; Mark Poulter; Paresh Shah; James Uphill; Tracy Campbell; Huda Al-Dujaily; Holger Hummerich; Jon Beck; Charles A Mein; Claudio Verzilli; John Whittaker; Michael P Alpers; John Collinge
Journal:  N Engl J Med       Date:  2009-11-19       Impact factor: 91.245

10.  Experimental transmission of Creutzfeldt-Jakob disease and related diseases to rodents.

Authors:  J Tateishi; T Kitamoto; M Z Hoque; H Furukawa
Journal:  Neurology       Date:  1996-02       Impact factor: 9.910

View more
  8 in total

1.  Protein folding, misfolding and aggregation: The importance of two-electron stabilizing interactions.

Authors:  Andrzej Stanisław Cieplak
Journal:  PLoS One       Date:  2017-09-18       Impact factor: 3.240

2.  Intrinsic toxicity of the cellular prion protein is regulated by its conserved central region.

Authors:  Graham P Roseman; Bei Wu; Mark A Wadolkowski; David A Harris; Glenn L Millhauser
Journal:  FASEB J       Date:  2020-05-08       Impact factor: 5.191

3.  Transmission of Soluble and Insoluble α-Synuclein to Mice.

Authors:  Daryl Rhys Jones; Marion Delenclos; AnnMarie T Baine; Michael DeTure; Melissa E Murray; Dennis W Dickson; Pamela J McLean
Journal:  J Neuropathol Exp Neurol       Date:  2015-12       Impact factor: 3.685

Review 4.  Cell biology of prion strains in vivo and in vitro.

Authors:  Daniel Shoup; Suzette A Priola
Journal:  Cell Tissue Res       Date:  2022-02-02       Impact factor: 5.249

5.  Dodecylphosphocholine Micelles Induce Amyloid Formation of the PrP(110-136) Peptide via an α-Helical Metastable Conformation.

Authors:  Simon Sauvé; Yves Aubin
Journal:  PLoS One       Date:  2016-12-08       Impact factor: 3.240

6.  Oxidative and Inflammatory Events in Prion Diseases: Can They Be Therapeutic Targets?

Authors:  Kedar N Prasad; Stephen C Bondy
Journal:  Curr Aging Sci       Date:  2019

7.  Sporadic Creutzfeldt-Jakob disease prion infection of human cerebral organoids.

Authors:  Bradley R Groveman; Simote T Foliaki; Christina D Orru; Gianluigi Zanusso; James A Carroll; Brent Race; Cathryn L Haigh
Journal:  Acta Neuropathol Commun       Date:  2019-06-14       Impact factor: 7.801

8.  A novel Gerstmann-Sträussler-Scheinker disease mutation defines a precursor for amyloidogenic 8 kDa PrP fragments and reveals N-terminal structural changes shared by other GSS alleles.

Authors:  Robert C C Mercer; Nathalie Daude; Lyudmyla Dorosh; Ze-Lin Fu; Charles E Mays; Hristina Gapeshina; Serene L Wohlgemuth; Claudia Y Acevedo-Morantes; Jing Yang; Neil R Cashman; Michael B Coulthart; Dawn M Pearson; Jeffrey T Joseph; Holger Wille; Jiri G Safar; Gerard H Jansen; Maria Stepanova; Brian D Sykes; David Westaway
Journal:  PLoS Pathog       Date:  2018-01-16       Impact factor: 6.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.